Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV

AIDS

Volumn 21, Issue SUPPL. 4, 2007, Pages

  Palombi, Leonardo ^a,b   Marazzi, Maria Cristina ^b,c   Voetberg, Albertus ^d   Magid, N Abdul ^e   Bartolo, Michelangelo ^f   Bestagini, Piero ^g   Bortolot, Gabriella ^g   Germano, Paola ^g   San Lio, Massimo Magnano ^g   Tintisona, Graziella ^g   Buonomo, Ersilia ^b   Doro Altan, Anna Maria ^b   Liotta, Giuseppe ^b   Mancinelli, Sandro ^b   Scarcella, Paola ^b   Guidotti, Giovanni ^h   Nielsen Saines, Karin ⁱ  

^a DREAM Program   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c LUMSA UNIVERSITY   (Italy)

^d WORLD BANK   (United States)

^e Machava General Hospital   (Mozambique)

^f MOLINETTE HOSPITAL   (Italy)

^g Community of Sant'Egidio ^*  (Italy)

^h ISTITUTO SUPERIORE DI SANITÀ   (Italy)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breastfeeding; DREAM Program; HIV; Mother to child transmission; Treatment acceleration program (TAP)

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN;

ARTICLE; ARTIFICIAL MILK; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; GESTATIONAL AGE; HEALTH PROGRAM; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT MORTALITY; MAJOR CLINICAL STUDY; MALAWI; MOZAMBIQUE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TANZANIA; TREATMENT DURATION; VIRUS LOAD; WEIGHT CHANGE;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BOTTLE FEEDING; BREAST FEEDING; DISEASE TRANSMISSION, VERTICAL; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT NUTRITION PHYSIOLOGY; INFANT, NEWBORN; MILK, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROGRAM EVALUATION; REGIONAL MEDICAL PROGRAMS;

EID: 34447315041     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000279708.09180.f5     Document Type: Article

References (31)

1. Marazzi MC, Guidotti G, Liotta G, Palombi L. DREAM: an integrated faith-based initiative to treat HIV/AIDS in Mozambique, case study. Perspectives and practice in antiretroviral treatment. Community of Sant' Egidio and Geneva: World Health Organization; 2005. Available at: http://www.who.int/ hiv/pub/casestudies/mozambiquedream.pdf.
2. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-1153.
3. Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Nunn A, Chintu C, Gibb DM, the CHAP Trial Team. Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial. J Acquir Immune Defic Syndr 2006; 42:637-645.
4. Bronzan RN, Taylor TE, Mwenechanya J, Tembo M, Kayira K, Bwanaisa L, et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis 2007; 195:895-904.
5. Minga A, Danel C, Abo Y, Dohoun L, Bonard D, Coulibaly A, et al., the ANRS 1220 Study Group. Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire. Bull World Health Organ 2007; 85:116-123.
6. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al., the Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration andART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
7. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-1243.
8. Palombi L. Oral Presentation, Meeting on "Sustaining Treatment Costs: Who Will Pay?" Co-hosted by WHO, UNAIDS, World Bank. Washington, November 27, 2006.
9. Temmerman M, Quaghebeur A, Mwanyumba F, Mandaliya K. Mother-to-child HIV transmission in resource poor settings: how to improve coverage? AIDS 2003; 17:1239-1242.
10. Stringer EM, Sinkala M, Stringer JS, Mzyece E, Makuka I, Goldenberg RL, et al. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS 2003; 17:1377-1382.
11. Marazzi MC, Germano P, Liotta G, Guidotti G, Louriero S, Gomes AD, et al. Implementation of antiretroviral triple therapy to prevent mother-to-child transmission: a public health approach in resource-limited settings. Eur J Pediatr 2007; [Epub ahead of print Jan 18].
12. Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42:610-613.
13. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
14. Martinson NA, Ekouevi DK, Dabis F, Morris L, Lupodwana P, Tonwe-Gold B, et al. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2007; [Epub ahead of print Apr 12].
15. Marazzi MC, Bartolo M, Emberti Gialloreti L, Germano P, Guidotti G, Liotta G, et al. Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique. Health Educ Res 2006; 21:34-42.
16. Bellocci MC, Forbici F, Palombi L, Gori C, Coelho E, Svicher C, et al. Subtype analysis and mutations to antiviral drugs in HIV-1 infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM Programme. J Med Virol 2005; 76:452-458.
17. Giuliano M, Guidotti G, Andreotti M, Pirillo MF, Villani P, Liotta G, et al. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load (a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program). J Acquir Immune Defic Syndr 2007; 44:286-291.
18. Giuliano M, Guidotti G, Andreotti M, Liotta G, Cusato M, Marazzi MC, et al. Triple therapy during pregnancy and after delivery significantly reduces breastmilk viral load: a substudy of the DREAM program [abstract No. 727]. In: Abstracts of the 13th Conference on Retrovirus and Opportunistic Infections (CROI); 5-9 February 2006; Denver. p. 313.
19. Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, Da Cruz Gomes A, Valls Blazquez MC, Narciso P, Perno CF, Mancinelli S, Palombi, et al. Safety of nevirapine-containing ARV triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1 infected pregnant women. HIV Medicine 2006; 7:338-344.
20. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA 2002; 288:189-198.
21. Cartmell E, Natalal H, François I, Ferreira MH, Grahnquist L. Nutritional and clinical status of children admitted to the malnutrition ward, Maputo central hospital: a comparison of data from 2001 and 1983. J Trop Pediatr 2005 Apr; 51(2):102-1025. Epub 2005 Jan 26.
22. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa and Uganda (Petra study): a randomised double-blind, placebo-controlled trial. Lancet 2002; 359:1178-1196.
23. Nolan ML, Greenberg AL, Fowler MG. A review of clinical trial to prevent mother-to-child transmission in Africa and inform rational intervention strategies. AIDS 2002; 16:1991-1999.
24. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-868.
25. Coovadia HM. Prevention and treatment of perinatal HIV-1 infection in the developing world. Curr Opin Infect Dis 2000; 13:247-251.
26. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al., the Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228.
27. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1. JAMA 2000; 283:1167-1174.
28. Miotti PG, Taha TET, Kumwenda NI, Broadhead R, Mtimavalye LA, Van der Hoeven L, et al. HIV transmission from breastfeeding: a study in Malawi. JAMA 1999; 282:744-749.
29. Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, Bennish ML, Newell ML. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369:1107-1116.
30. Taha TE, Kumwenda NI, Hoover DR, Kafulafula G, Fiscus SA, Nkhoma C, et al. The impact of breastfeeding on the health of HIV-positive mothers and their children in sub-Saharan Africa. Bull World Health Organ 2006; 84:546-554.
31. Cartmell E, Natalal H, Francois I, Ferreira MH, Grahnquist L. Nutritional and clinical status of children admitted to the malnutrition ward, Maputo Central Hospital: a comparison of data from 2001 and 1983. J Trop Pediatr 2005; 51:102-105. [Epub 2005 ahead of print Jan 26].